InMode Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 9.8
- Dividend yield
- –
About InMode
Electromedical & Electrotherapeutic Apparatus, SIC 3845
InMode Ltd. designs, manufactures, and commercializes minimally invasive and non-invasive medical and surgical systems. The company develops energy-based aesthetic treatment platforms, offering equipment, consumables, and related maintenance services. Its product lines encompass multiple branded platforms such as BodyTite, Morpheus8, Optimas, EvolveX, EmpowerRF, Triton, Votiva, Luxora, and ApexRF. These systems serve clinical applications across aesthetic surgery, plastic surgery, dermatology, gynecology, and ophthalmology. InMode provides these products to a diverse base of healthcare professionals, including plastic surgeons, dermatologists, obstetricians and gynecologists, otolaryngologists, ophthalmologists, and aesthetic medical practitioners.
The company maintains its corporate headquarters in Yokneam, Israel. InMode distributes and sells its technology globally to medical providers, generating revenues across North America, Europe, Asia, and other international markets, with specific operational entities in the United States and Israel. The organization conducts research, development, and commercial operations through domestic and international subsidiaries, while outsourcing the physical manufacturing of its aesthetic hardware to specialized external subcontractors.
Summary of the business section of InMode's latest annual report, written by StockData.
Company profile
Company
- Legal name
- InMode Ltd.
- Founded
- 2008
- Headquarters
- Yokneam, L3
- Address
- Tavor Building, Sha?Ar Yokneam, Pob 533 2069200
- Phone
- 972-4-9097470
- Employees
- 660, Dec 31, 2025
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Kesselman & Kesselman, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- INMD
- Exchange
- Nasdaq
- IPO date
- Aug 8, 2019
- Shares outstanding
- 63M, Dec 31, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Feb 10, 2022; 2-for-1, Oct 1, 2021
- SEC CIK
- 1742692
- CUSIP
- M5425M103
- ISIN
- USM5425M1038
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Kreindel | Chief Technology Officer, Director | 3,114,762 |
| Moshe Mizrahy | Chief Executive Officer, Director | 4,299,226 |
| Itzkovich Moshe | Chief Financial Officer | 40,733 |
| Michael Howard Dennison | President, North America | 7,654 |
| Yair Malca | Chief Financial Officer | 94,192 |
| Shlomo Nass | Director | 2,000 |
| Hadar Ron | Director | 60,270 |
| Nadav Kenneth | Director | 5,000 |
| Michael J. Anghel | Director | 9,000 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 660 employees worldwide, across four departments, including”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 8, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 5, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |